Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 results for Mirikizumab in Crohn's disease have been posted following completion of the trial. The status is completed, with results posted on 2024-12-2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-12-27